Synaptogenix Inc. (SNPX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
SNPX Chart
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token
Singular focus on Bittensor (TAO), the leading AI token by adoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK , June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altucher will lead a TAO-based revenue generation strategy targeting staking yield and token appreciation.
Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
$19.6 million in cash and cash equivalents as of September 30, 2024 Dramatically reduced cash burn rate expected NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding.
Synaptogenix Announces $5.0 Million Financing
NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "Registered Offering") and a concurrent private placement (the "Private Placement" and collectively with the Registered Offering, the "Offering") of additional shares of Preferred Stock and unregistered common stock purchase warrants.
Synaptogenix Inc. Dividends
Synaptogenix Inc. Earnings
| 28 May 2025 Date | | - Cons. EPS | 0.04 EPS |
| 27 Nov 2024 Date | | - Cons. EPS | - EPS |
| 16 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
| 1 Apr 2024 Date | | - Cons. EPS | - EPS |
| 28 May 2025 Date | | - Cons. EPS | 0.04 EPS |
| 27 Nov 2024 Date | | - Cons. EPS | - EPS |
| 16 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
| 1 Apr 2024 Date | | - Cons. EPS | - EPS |
Synaptogenix Inc. (SNPX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Synaptogenix Inc. ever had a stock split?
Synaptogenix Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Alan J. Tuchman M.D., MBA(FAAN) CEO | NASDAQ (CM) Exchange | 87167T201 Cusip |
| US Country | 4 Employees | - Last Dividend | 5 Apr 2024 Last Split | 8 Dec 2020 IPO Date |
Overview
Synaptogenix, Inc. is a biopharmaceutical company engaged in the development of innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Incorporated in 2012 and based in New York, New York, Synaptogenix is dedicated to advancing its product candidates through pre-clinical and clinical development stages. The company's research and development efforts are centered on a drug candidate known as Bryostatin-1, which shows promise for not only Alzheimer's disease but potentially for a range of other cognitive diseases and dysfunctions.
Products and Services
- Bryostatin-1 for Alzheimer's Disease
Synaptogenix's flagship product, Bryostatin-1, is under development as a treatment for Alzheimer's disease. This drug candidate is based on extensive research and is currently in various stages of clinical development. Bryostatin-1 has been shown to have potential in restoring synaptic density and function, which are often diminished in Alzheimer's patients.
- Bryostatin-1 for Other Neurodegenerative or Cognitive Diseases and Dysfunctions
Beyond Alzheimer's disease, Synaptogenix is exploring the therapeutic applications of Bryostatin-1 for a variety of other neurodegenerative or cognitive disorders. This includes fragile X syndrome, multiple sclerosis, and Niemann-Pick type C disease. The versatility of Bryostatin-1 demonstrates Synaptogenix's commitment to addressing the broader spectrum of cognitive diseases and dysfunctions, potentially offering hope to patients with conditions that currently have limited treatment options.
Contact Information
